CoChat
Sign Up
Cited by 555Cancer survivorship and carePharmacovigilance and Adverse Drug ReactionsStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30

Fromme, Erik K., Eilers, Kristine M., Mori, Motomi, Hsieh, Yi-Ching, Beer, Tomasz M.·2004·Journal of Clinical Oncology
DOI 10.1200/jco.2004.03.025
Open this paper in CoChat — free account

Abstract

Purpose: Adverse events in chemotherapy clinical trials are assessed and reported by clinicians, yet clinician accuracy in assessing symptoms has been questioned. We compared patient reporting of eight symptoms using a validated instrument, the European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (QLQ-C30 or QLQ) with physicians' reporting of the same symptoms in the study's adverse events log. Patients and Methods: Thirty-seven men with metastatic, androgen-independent prostate cancer enrolled onto a phase II trial of weekly calcitriol and docetaxel completed the QLQ every 4 weeks for up to 28 weeks. A patient-reported symptom was defined as an increase in a QLQ symptom score by at least 10 points (0 to 100 scale), sustained for at least 4 weeks. A physician-reported symptom was considered present if it was ever documented in the adverse event log. Results: Forty-nine (new or worsened) symptoms were detected by both physician and QLQ, 48 symptoms were detected by the physician alone, and 55 symptoms were detected by the QLQ alone. They agreed on the absence of a symptom in 102 instances of 254 possible opportunities. Their uncorrected agreement was 59.4%, but Cohen's κ, a coefficient of agreement that corrects for chance, was 0.15, indicating only slight agreement. Using the QLQ as the standard, overall physician sensitivity and specificity was 47% and 68%, respectively, although it varied considerably among symptoms. Conclusion: Even in a tightly controlled clinical trial, physician reporting was neither sensitive nor specific in detecting common chemotherapy adverse effects. Tools for collecting patient-reported adverse event data in chemotherapy clinical trials should be developed.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2004.03.025

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 3

  1. Ingham J, Portenoy RK: The measurement of pain and other symptoms, in Doyle D, Hanks G, MacDonald N (eds): Oxford Textbook of Palliative Medicine (ed 2) . Oxford, Oxford University Press, pp 203,2001-222
  2. Bruera E: Research into symptoms other than pain, in Doyle D, Hanks GWC, MacDonald N (eds): Oxford Textbook of Palliative Medicine (ed 2) . Oxford, Oxford University Press, pp 180,1998
  3. 10.1023/A:1008886200225 · DOI

Cited by

Sorted by citations

See all 555

Related

See all

Metadata

Authors
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Beer, Tomasz M.
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2004-09-01
Volume
22
Issue
17
Pages
3485-3490
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2004.03.025
OpenAlex
W2150906637
Cited by
555
References
32
Citations by year
2026: 12 · 2025: 15 · 2024: 40 · 2023: 35 · 2022: 56 · 2021: 41 · 2020: 45 · 2019: 34 · 2018: 38 · 2017: 44 · 2016: 32 · 2015: 32 · 2014: 17 · 2013: 17 · 2012: 14
FWCI
4.16
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (P30 CA 69533, P30CA069533)
  • National Center for Research Resources (3 M01RR00334-33S2, M01RR000334)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
chemotherapy side effects, patient-reported symptoms, EORTC QLQ-C30, castration-resistant prostate cancer, metastatic prostate cancer, docetaxel, 1,25-dihydroxyvitamin D3, adverse event reporting, quality of life assessment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Physicians, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Adverse Drug Reaction Reporting Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review